Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial

BACKGROUND: Animal and cellular studies support the importance of autophagy inhibition in lymphangioleiomyomatosis (LAM). In a cohort of subjects with LAM, we tested the hypothesis that treatment with sirolimus and hydroxychloroquine (an autophagy inhibitor) at two different dose levels is safe and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Chest
Main Authors: El-Chemaly, Souheil, Taveira-Dasilva, Angelo, Goldberg, Hilary J., Peters, Elizabeth, Haughey, Mary, Bienfang, Don, Jones, Amanda M., Julien-Williams, Patricia, Cui, Ye, Villalba, Julian A., Bagwe, Shefali, Maurer, Rie, Rosas, Ivan O., Moss, Joel, Henske, Elizabeth P.
Formato: Artigo
Idioma:Inglês
Publicado em: American College of Chest Physicians 2017
Assuntos:
Diffuse Lung Disease
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6026235/
https://ncbi.nlm.nih.gov/pubmed/28192114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.chest.2017.01.033
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados